Carisoprodol

Last updated

Carisoprodol
Carisoprodol.svg
Clinical data
Pronunciation /kərˌaɪsʌˈproʊdɒl/
kahr-EYE-suh-PROH-dol
Trade names Soma, others [1]
AHFS/Drugs.com Monograph
MedlinePlus a682578
License data
Pregnancy
category
  • C
Addiction
liability 		Moderate [2]
Routes of
administration 		By mouth
Drug class muscle relaxant
sedative
carbamate
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding 60%
Metabolism Liver (CYP2C19-mediated)
Metabolites Meprobamate
Onset of action Rapid (30 minutes [3] [ failed verification ])
Elimination half-life 2.5 hours [12 hours [nb 1] ]
Excretion Kidney
Identifiers
  • (RS)-2-{[(aminocarbonyl)oxy]methyl}-2-methylpentyl isopropylcarbamate
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.001.017 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C12H24N2O4
Molar mass 260.334 g·mol−1
3D model (JSmol)
  • O=C(N)OCC(C)(CCC)COC(=O)NC(C)C
  • InChI=1S/C12H24N2O4/c1-5-6-12(4,7-17-10(13)15)8-18-11(16)14-9(2)3/h9H,5-8H2,1-4H3,(H2,13,15)(H,14,16) Yes check.svgY
  • Key:OFZCIYFFPZCNJE-UHFFFAOYSA-N Yes check.svgY
   (verify)

Carisoprodol, sold under the brand name Soma among others, is a medication used for musculoskeletal pain. [4] Use is only approved for up to three weeks. [4] Effects generally begin within half an hour and last for up to six hours. [4] It is taken orally. [4]

Contents

Common side effects include headache, dizziness, and sleepiness. [4] Serious side effect may include addiction, allergic reactions, and seizures. [4] In people with a sulfa allergy certain formulations may result in problems. [4] Safety during pregnancy and breastfeeding is not clear. [4] [5] How it works is not clear. [4] Some of its effects are believed to occur following being converted into meprobamate. [4]

Carisoprodol was approved for medical use in the United States in 1959. [4] Its approval in the European Union was withdrawn in 2008. [6] It is available as a generic medication. [4] In 2019, it was the 343rd most commonly prescribed medication in the United States, with more than 800 thousand prescriptions. [7] In the United States, it is a Schedule IV controlled substance. [4]

Medical uses

Somadril Comp. - combination muscle relaxant medication containing carisoprodol, paracetamol (acetaminophen), and caffeine Somadril.JPG
Somadril Comp. – combination muscle relaxant medication containing carisoprodol, paracetamol (acetaminophen), and caffeine

Carisoprodol is meant to be used along with rest, physical therapy and other measures to relax muscles after strains, sprains and muscle injuries. [8] It comes in tablet format and is taken by the mouth three times a day and before bed. [8]

Side effects

The usual dose of 350 mg is unlikely to engender prominent side effects other than somnolence, and mild to significant euphoria or dysphoria, but the euphoria is generally short-lived due to the fast metabolism of carisoprodol into meprobamate and other metabolites; the euphoria derived is, according to new research[ citation needed ], most likely due to carisoprodol's inherent, potent anxiolytic effects that are far stronger than those produced by its primary metabolite, meprobamate, which is often misblamed for the drug-seeking associated with carisoprodol, as carisoprodol itself is responsible for the significantly more intense central nervous system effects than meprobamate alone. Carisoprodol has a qualitatively different set of effects to that of meprobamate (Miltown). The medication is well tolerated and without adverse effects in the majority of patients for whom it is indicated. In some patients, however, and/or early in therapy, carisoprodol can have the full spectrum of sedative side effects and can impair the patient's ability to operate a firearm, motor vehicles, and other machinery of various types, especially when taken with medications containing alcohol, in which case an alternative medication would be considered. The intensity of the side effects of carisoprodol tends to lessen as therapy continues, as is the case with many other drugs. Other side effects include: dizziness, clumsiness, headache, fast heart rate, upset stomach, vomiting and skin rash. [8]

The interaction of carisoprodol with essentially all opioids, and other centrally acting analgesics, but especially codeine, those of the codeine-derived subgroup of the semisynthetic class (ethylmorphine, dihydrocodeine, hydrocodone, oxycodone, nicocodeine, benzylmorphine, the various acetylated codeine derivatives including acetyldihydrocodeine, dihydroisocodeine, nicodicodeine and others) which allows the use of a smaller dose of the opioid to have a given effect, is useful in general and especially where skeletal muscle injury and/or spasm is a large part of the problem. The potentiation effect is also useful in other pain situations and is also especially useful with opioids of the open-chain class, such as methadone, levomethadone, ketobemidone, phenadoxone and others. In recreational drug users, deaths have resulted from combining doses of hydrocodone and carisoprodol. Another danger of misuse of carisoprodol and opiates is the potential to asphyxiate while unconscious.[ citation needed ]

Meprobamate and other muscle-relaxing drugs often were subjects of misuse in the 1950s and 60s. [9] [10] Overdose cases were reported as early as 1957, and have been reported on several occasions since then. [11] [12] [13] [14] [15] [16] [17]

Carisoprodol is metabolized by the liver and excreted by the kidneys, so this drug must be used with caution with patients that have impaired hepatic or renal function. [18] Because of potential for more severe side effects, this drug is on the list to avoid for elderly people. [19]

Withdrawal

Carisoprodol, meprobamate, and related drugs such as tybamate, have the potential to produce physical dependence of the barbiturate type following periods of prolonged use. Withdrawal of the drug after extensive use may require hospitalization in medically compromised patients. In severe cases the withdrawal can mimic the symptoms of alcohol withdrawal including the potentially lethal status epilepticus.

Psychological dependence has also been linked to carisoprodol use [20] although this is much less severe than with meprobamate itself (presumably due to the slower onset of effects). Psychological dependence is more common in those who use carisoprodol non-medically and those who have a history of substance use (particularly sedatives or alcohol). It may reach clinical significance before physiological tolerance and dependence have occurred and (as with benzodiazepines) has been demonstrated to persist to varying degrees of severity for months or years after discontinuation.

Discontinuation of carisoprodol, as with all GABA-ergics, can result in cognitive changes which persist for weeks, months, or rarely even years including greatly increased anxiety and depression, social withdrawal, hair-trigger agitation/aggression, chronic insomnia, new or aggravated (often illogical) phobias, reduced IQ, short term and long-term memory loss, and dozens of other sequelae. [21] The effects, severity, and duration appear to be slightly dose-dependent but are mainly determined by the patients pattern of use (taken as prescribed, taken in bulk doses, mixed with other drugs, a combination of the above, etc.), genetic predisposition to substance use, and a history of substance use all increase the patients risk of persistent discontinuation syndrome symptoms.

Treatment for physical withdrawal generally involves switching the patient to a long-acting benzodiazepine such as diazepam or clonazepam then slowly titrating them off the replacement drug completely at a rate which is both reasonably comfortable for the patient but rapid enough for the managing physician to consider the rate of progress acceptable (overly rapid dose reduction greatly increases the risk of patient non-compliance such as the use of illicitly obtained alternative sedatives and/or alcohol). Psychotherapy and cognitive behavioral therapy have demonstrated moderate success in reducing the rebound anxiety which results upon carisoprodol discontinuation but only when combined with regular and active attendance to a substance use support group.[ citation needed ]

Carisoprodol withdrawal can be life-threatening (especially in high dose users and those who attempt to quit "cold turkey"). Medical supervision is recommended, with gradual reduction of dose of carisoprodol or a substituted medication, typical of other depressant drugs.

Non-medical use

Combining a muscle relaxant like carisoprodol with opioids and benzodiazepines is referred to as "The Holy Trinity" as it has been reported to increase the power of the "high". [22]

Recreational users of carisoprodol usually seek its potentially heavy sedating, relaxant, and anxiolytic effects. [23] Also, because of its potentiating effects on narcotics, it is often used in conjunction with many opioid drugs. Also it is not detected on standard drug testing screens. On 26 March 2010 the DEA issued a Notice of Hearing on proposed rule making in respect to the placement of carisoprodol in schedule IV of the Controlled Substances Act. [24] The DEA ended up classifying it under schedule IV. [25] Carisoprodol is sometimes mixed with date rape drugs. [26]

Overdose

As with other GABAergic drugs, combination with other drugs that depress the respiratory system, such as alcohol, sedatives and opioids possess a significant risk to the user in the form of overdose. [27] Overdose symptoms are similar to those of other GABAergics including excessive sedation and unresponsiveness to stimuli, severe ataxia, amnesia, confusion, agitation, intoxication and inappropriate (potentially violent) behavior. Severe overdoses may present with respiratory depression (and subsequent pulmonary aspiration), coma, and death. [28]

Carisoprodol is not detected on all toxicology tests which may delay diagnosis of overdose. Overdose symptoms in combination with opiates are similar but are distinguished by the presentation of normal or pinpoint pupils, which are generally unresponsive to light. Carisoprodol (as with its metabolite meprobamate) is particularly dangerous in combination with alcohol. Flumazenil (the benzodiazepine antidote) is not effective in the management of carisoprodol overdose as carisoprodol acts at the barbiturate binding site. Treatment mirrors that of barbiturate overdoses and is generally supportive, including the administration of mechanical respiration and pressors as indicated and, in rare cases, bemegride. Total amnesia of the experience is not uncommon following recovery.[ citation needed ]

In 2014 actress Skye McCole Bartusiak died of an overdose due to the combined effects of carisoprodol, hydrocodone and difluoroethane. [29]

Pharmacology

Pharmacodynamics

Carisoprodol, has a chemical structure similar to glutamate, a neurotransmitter, and dimethylglycine.

Carisoprodol's structural similarity to meprobamate indicates GABAergic activity, including GABAA agonism, similar to the mechanism of benzodiazepines. [30] This will allow for further muscle relaxation and anxiety reduction. Therefore, carisoprodol, at low to moderate dosages, may be clinically indicated for absent seizures, yet exacerbate tonic-clonic seizures.[ medical citation needed ]

Pharmacokinetics

Carisoprodol has a rapid, 30-minute onset of action, with the aforementioned effects lasting about two to six hours. It is metabolized in the liver via the cytochrome P450 oxidase isozyme CYP2C19, excreted by the kidneys and has about an eight-hour half-life. In patients with low levels of CYP2C19 (poor metabolizers), standard doses can lead to increased concentrations of carisoprodol (up-to a four-fold increase). [31] A considerable proportion of carisoprodol is metabolized to meprobamate, which is a known addictive substance; this could account for the addictive potential of carisoprodol (meprobamate levels reach higher peak plasma levels than carisoprodol itself following administration).

It is slightly soluble in water and freely soluble in ethanol, chloroform and acetone. The drug's solubility is practically independent of pH.

History

On 1 June 1959, several American pharmacologists convened at Wayne State University in Detroit, Michigan to discuss a newly discovered structural analogue of meprobamate. The substitution of one hydrogen atom with an isopropyl group on one of the carbamyl nitrogens was intended to yield a drug with new pharmacological properties. It had been developed by Frank Berger at Wallace Laboratories and was named carisoprodol. [32]

Building on meprobamate's pharmacological effects, carisoprodol was intended to have better muscle relaxing properties, less potential for addiction, and a lower risk of overdose. Carisoprodol's effect profile did indeed turn out to differ significantly with respect to meprobamate, with carisoprodol possessing stronger muscle relaxant and analgesic effects. [33]

Norway

Reports from Norway have shown carisoprodol has addictive potential [34] as a prodrug of meprobamate and/or potentiator of hydrocodone, oxycodone, codeine, and similar drugs. In May 2008 it was taken off the market in Norway. [35]

European Union

In the EU, the European Medicines Agency issued a release recommending member states suspend marketing authorization for this product in the treatment of acute (not chronic) back pain. [36]

As of November 2007, carisoprodol has been taken off the market in Sweden due to problems with dependence and side effects. The agency overseeing pharmaceuticals considered other drugs used with the same indications as carisoprodol to have the same or better effects without the risks of the drug. [37]

United States

Until 12 December 2011, when the administrator of the Drug Enforcement Administration (DEA) issued the final ruling placing the substance carisoprodol into Schedule IV of the Controlled Substances Act (CSA), carisoprodol was not a controlled substance. The placement of carisoprodol into Schedule IV was effective 11 January 2012. [38]

Carisoprodol is available generically as 350 mg and, more recently, 250 mg tablets. Compounded tablets with acetaminophen and codeine are also available. [39]

Canada

Federally, carisoprodol is a prescription drug (Schedule I, sub-schedule F1). [40] Provincial regulations vary. [41] It is no longer readily available.[ medical citation needed ]

Indonesia

Notes

  1. ↑ At least 25% of the carisoprodol in the body is transformed by the liver into meprobamate, its main active metabolite, which in turn has a half-life of 10 hours. [3]

Related Research Articles

<span class="mw-page-title-main">Benzodiazepine</span> Class of depressant drugs

Benzodiazepines, colloquially called "benzos", are a class of depressant drugs whose core chemical structure is the fusion of a benzene ring and a diazepine ring. They are prescribed to treat conditions such as anxiety disorders, insomnia, and seizures. The first benzodiazepine, chlordiazepoxide (Librium), was discovered accidentally by Leo Sternbach in 1955, and was made available in 1960 by Hoffmann–La Roche, which followed with the development of diazepam (Valium) three years later, in 1963. By 1977, benzodiazepines were the most prescribed medications globally; the introduction of selective serotonin reuptake inhibitors (SSRIs), among other factors, decreased rates of prescription, but they remain frequently used worldwide.

<span class="mw-page-title-main">Flunitrazepam</span> Benzodiazepine sedative

Flunitrazepam, also known as Rohypnol among other names, is a benzodiazepine used to treat severe insomnia and assist with anesthesia. As with other hypnotics, flunitrazepam has been advised to be prescribed only for short-term use or by those with chronic insomnia on an occasional basis.

<span class="mw-page-title-main">Hydrocodone</span> Opioid drug used in pain relief

Hydrocodone, also known as dihydrocodeinone, is a semisynthetic opioid used to treat pain and as a cough suppressant. It is taken by mouth. Typically it is dispensed as the combination acetaminophen/hydrocodone or ibuprofen/hydrocodone for pain severe enough to require an opioid and in combination with homatropine methylbromide to relieve cough. It is also available by itself in a long-acting form under the brand name Zohydro ER, among others, to treat severe pain of a prolonged duration. Hydrocodone is a controlled drug: in the United States a Schedule II Controlled Substance.

<span class="mw-page-title-main">Diazepam</span> Benzodiazepine sedative


Diazepam, sold under the brand name Valium among others, is a medicine of the benzodiazepine family that acts as an anxiolytic. It is used to treat a range of conditions, including anxiety, seizures, alcohol withdrawal syndrome, muscle spasms, insomnia, and restless legs syndrome. It may also be used to cause memory loss during certain medical procedures. It can be taken orally, as a suppository inserted into the rectum, intramuscularly, intravenously or used as a nasal spray. When injected intravenously, effects begin in one to five minutes and last up to an hour. When taken by mouth, effects begin after 15 to 60 minutes.

<span class="mw-page-title-main">Temazepam</span> Insomnia medication

Temazepam, sold under the brand name Restoril among others, is a medication of the benzodiazepine class which is generally used to treat severe or debilitating insomnia. It is taken by mouth. Temazepam is rapidly absorbed, and significant hypnotic effects begin in less than 30 minutes and can last for up to eight hours. Prescriptions for hypnotics such as temazepam have seen a dramatic decrease since 2010, while anxiolytics such as alprazolam, clonazepam, and lorazepam have increased or remained stable. Temazepam and similar hypnotics, such as triazolam (Halcion) are generally reserved for severe and debilitating insomnia. They have largely been replaced by z-drugs and atypical antidepressants as first line treatment for insomnia.

<span class="mw-page-title-main">Alprazolam</span> Benzodiazepine medication

Alprazolam, sold under the brand name Xanax and others, is a fast-acting, potent tranquilizer of moderate duration within the triazolobenzodiazepine group of chemicals called benzodiazepines. Alprazolam is most commonly prescribed in the management of anxiety disorders, especially panic disorder and generalized anxiety disorder (GAD). Other uses include the treatment of chemotherapy-induced nausea, together with other treatments. GAD improvement occurs generally within a week. Alprazolam is generally taken orally.

<span class="mw-page-title-main">Sedative</span> Drug that reduces excitement without inducing sleep

A sedative or tranquilliser is a substance that induces sedation by reducing irritability or excitement. They are CNS depressants and interact with brain activity causing its deceleration. Various kinds of sedatives can be distinguished, but the majority of them affect the neurotransmitter gamma-aminobutyric acid (GABA). In spite of the fact that each sedative acts in its own way, most produce relaxing effects by increasing GABA activity.

<span class="mw-page-title-main">Hydromorphone</span> Opioid medication used for pain relief

Hydromorphone, also known as dihydromorphinone, and sold under the brand name Dilaudid among others, is a morphinan opioid used to treat moderate to severe pain. Typically, long-term use is only recommended for pain due to cancer. It may be used by mouth or by injection into a vein, muscle, or under the skin. Effects generally begin within half an hour and last for up to five hours. A 2016 Cochrane review found little difference in benefit between hydromorphone and other opioids for cancer pain.

Colloquially known as "downers", depressants or central depressants are drugs that lower neurotransmission levels, or depress or reduce arousal or stimulation in various areas of the brain. Depressants do not change the mood or mental state of others. Stimulants, or "uppers", increase mental or physical function, hence the opposite drug class from depressants are stimulants, not antidepressants.

<span class="mw-page-title-main">Dihydrocodeine</span> Opioid

Dihydrocodeine is a semi-synthetic opioid analgesic prescribed for pain or severe dyspnea, or as an antitussive, either alone or compounded with paracetamol (acetaminophen) or aspirin. It was developed in Germany in 1908 and first marketed in 1911.

Physical dependence is a physical condition caused by chronic use of a tolerance-forming drug, in which abrupt or gradual drug withdrawal causes unpleasant physical symptoms. Physical dependence can develop from low-dose therapeutic use of certain medications such as benzodiazepines, opioids, stimulants, antiepileptics and antidepressants, as well as the recreational misuse of drugs such as alcohol, opioids and benzodiazepines. The higher the dose used, the greater the duration of use, and the earlier age use began are predictive of worsened physical dependence and thus more severe withdrawal syndromes. Acute withdrawal syndromes can last days, weeks or months. Protracted withdrawal syndrome, also known as post-acute-withdrawal syndrome or "PAWS", is a low-grade continuation of some of the symptoms of acute withdrawal, typically in a remitting-relapsing pattern, often resulting in relapse and prolonged disability of a degree to preclude the possibility of lawful employment. Protracted withdrawal syndrome can last for months, years, or depending on individual factors, indefinitely. Protracted withdrawal syndrome is noted to be most often caused by benzodiazepines. To dispel the popular misassociation with addiction, physical dependence to medications is sometimes compared to dependence on insulin by persons with diabetes.

<span class="mw-page-title-main">Meprobamate</span> Carbamate derivative used as an anxiolytic drug

Meprobamate—marketed as Miltown by Wallace Laboratories and Equanil by Wyeth, among others—is a carbamate derivative used as an anxiolytic drug. It was the best-selling minor tranquilizer for a time, but has largely been replaced by the benzodiazepines due to their wider therapeutic index and lower incidence of serious side effects.

<span class="mw-page-title-main">Etizolam</span> Benzodiazepine analog drug

Etizolam is a thienodiazepine derivative which is a benzodiazepine analog. The etizolam molecule differs from a benzodiazepine in that the benzene ring has been replaced by a thiophene ring and triazole ring has been fused, making the drug a thienotriazolodiazepine.

<span class="mw-page-title-main">Chlordiazepoxide</span> Benzodiazepine class sedative and hypnotic medication

Chlordiazepoxide, trade name Librium among others, is a sedative and hypnotic medication of the benzodiazepine class; it is used to treat anxiety, insomnia and symptoms of withdrawal from alcohol and other drugs.

<span class="mw-page-title-main">Hydrocodone/paracetamol</span> Combination pain relief drug

Hydrocodone/paracetamol is the combination of the pain medications hydrocodone and paracetamol (acetaminophen). It is used to treat moderate to severe pain. It is taken by mouth. Recreational use is common in the United States.

<span class="mw-page-title-main">Codeine</span> Opiate and prodrug of morphine used to treat pain

Codeine is an opiate and prodrug of morphine mainly used to treat pain, coughing, and diarrhea. It is also commonly used as a recreational drug. It is found naturally in the sap of the opium poppy, Papaver somniferum. It is typically used to treat mild to moderate degrees of pain. Greater benefit may occur when combined with paracetamol (acetaminophen) or a nonsteroidal anti-inflammatory drug (NSAID) such as aspirin or ibuprofen. Evidence does not support its use for acute cough suppression in children or adults. In Europe, it is not recommended as a cough medicine in those under 12 years of age. It is generally taken by mouth. It typically starts working after half an hour, with maximum effect at two hours. Its effects last for about four to six hours. Codeine exhibits abuse potential similar to other opioid medications, including a risk of habituation and overdose.

<span class="mw-page-title-main">Opioid overdose</span> Toxicity due to excessive consumption of opioids

An opioid overdose is toxicity due to excessive consumption of opioids, such as morphine, codeine, heroin, fentanyl, tramadol, and methadone. This preventable pathology can be fatal if it leads to respiratory depression, a lethal condition that can cause hypoxia from slow and shallow breathing. Other symptoms include small pupils and unconsciousness; however, its onset can depend on the method of ingestion, the dosage and individual risk factors. Although there were over 110,000 deaths in 2017 due to opioids, individuals who survived also faced adverse complications, including permanent brain damage.

<span class="mw-page-title-main">Barbiturate</span> Class of depressant drugs derived from barbituric acid

Barbiturates are a class of depressant drugs that are chemically derived from barbituric acid. They are effective when used medically as anxiolytics, hypnotics, and anticonvulsants, but have physical and psychological addiction potential as well as overdose potential among other possible adverse effects. They have been used recreationally for their anti-anxiety and sedative effects, and are thus controlled in most countries due to the risks associated with such use.

<span class="mw-page-title-main">Opiate</span> Substance derived from opium

An opiate is an alkaloid substance derived from opium. It differs from the similar term opioid in that the latter is used to designate all substances, both natural and synthetic, that bind to opioid receptors in the brain. Opiates are alkaloid compounds naturally found in the opium poppy plant Papaver somniferum. The psychoactive compounds found in the opium plant include morphine, codeine, and thebaine. Opiates have long been used for a variety of medical conditions, with evidence of opiate trade and use for pain relief as early as the eighth century AD. Most opiates are considered drugs with moderate to high abuse potential and are listed on various "Substance-Control Schedules" under the Uniform Controlled Substances Act of the United States of America.

<span class="mw-page-title-main">Prescription drug addiction</span> Medical condition

Prescription drug addiction is the chronic, repeated use of a prescription drug in ways other than prescribed for, including using someone else’s prescription. A prescription drug is a pharmaceutical drug that may not be dispensed without a legal medical prescription. Drugs in this category are supervised due to their potential for misuse and substance use disorder. The classes of medications most commonly abused are opioids, central nervous system (CNS) depressants and central nervous stimulants. In particular, prescription opioid is most commonly abused in the form of prescription analgesics.

References

  1. ↑ "Carisoprodol". drugs.com. Retrieved 16 April 2017.
  2. ↑ "Drug Scheduling". DEA. Retrieved 24 March 2024.
  3. 1 2 Carrasco A (13 September 2019). "Letra C (Carisoprodol)". In Carrasco Ruiz MA, Chavez Pulido X, Morales E (eds.). Diccionario de Especialidades Farmaceúticas PLM (in Spanish). Vol. I (65th ed.). Mexico City: PLM Latinoamérica. p. 222. ISBN   978-607-625-072-3 . Retrieved 13 June 2021.
  4. 1 2 3 4 5 6 7 8 9 10 11 12 13 "Carisoprodol Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 8 April 2019.
  5. ↑ "DailyMed - carisoprodol tablet". dailymed.nlm.nih.gov. Retrieved 8 April 2019.
  6. ↑ "Carisoprodol". European Medicines Agency. 15 November 2007. Retrieved 8 April 2019.
  7. ↑ "Carisoprodol - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.
  8. 1 2 3 "Carisoprodol". MedlinePlus. National Library of Medicine. Retrieved 6 May 2019.
  9. ↑ Kamin I, Shaskan DA (June 1959). "Death due to massive overdose of meprobamate". The American Journal of Psychiatry. 115 (12): 1123–1124. doi:10.1176/ajp.115.12.1123-a. PMID   13649976.
  10. ↑ Hollister LE (1983). "The pre-benzodiazepine era". Journal of Psychoactive Drugs. 15 (1–2): 9–13. doi:10.1080/02791072.1983.10472117. PMID   6350551.
  11. ↑ Gaillard Y, Billault F, Pépin G (May 1997). "Meprobamate overdosage: a continuing problem. Sensitive GC-MS quantitation after solid phase extraction in 19 fatal cases". Forensic Science International. 86 (3): 173–180. doi:10.1016/S0379-0738(97)02128-2. PMID   9180026.
  12. ↑ Allen MD, Greenblatt DJ, Noel BJ (December 1977). "Meprobamate overdosage: a continuing problem". Clinical Toxicology. 11 (5): 501–515. doi:10.3109/15563657708988216. PMID   608316.
  13. ↑ Kintz P, Tracqui A, Mangin P, Lugnier AA (June 1988). "Fatal meprobamate self-poisoning". The American Journal of Forensic Medicine and Pathology. 9 (2): 139–140. doi:10.1097/00000433-198806000-00009. PMID   3381792.
  14. ↑ Eeckhout E, Huyghens L, Loef B, Maes V, Sennesael J (1988). "Meprobamate poisoning, hypotension and the Swan-Ganz catheter". Intensive Care Medicine. 14 (4): 437–438. doi:10.1007/BF00262904. PMID   3403779. S2CID   2784867.
  15. ↑ Lhoste F, Lemaire F, Rapin M (April 1977). "Treatment of hypotension in meprobamate poisoning". The New England Journal of Medicine. 296 (17): 1004. doi:10.1056/NEJM197704282961717. PMID   846530.
  16. ↑ Bedson HS (February 1959). "Coma due to meprobamate intoxication; report of a case confirmed by chemical analysis". Lancet. 1 (7067): 288–290. doi:10.1016/S0140-6736(59)90209-0. PMID   13632000.
  17. ↑ Blumberg AG, Rosett HL, Dobrow A (September 1959). "Severe hypotensive reactions following meprobamate overdosage". Annals of Internal Medicine. 51 (3): 607–612. doi:10.7326/0003-4819-51-3-607. PMID   13801701.
  18. ↑ "CARISOPRODOL". TOXNET. National Library of Medicine. Retrieved 6 May 2019.
  19. ↑ NCQA's HEDIS Measure: Use of High Risk Medications in the Elderly Archived 1 February 2010 at the Wayback Machine
  20. ↑ "What is Carisoprodol used for?". Pain o Soma medicines. 19 March 2021. Retrieved 29 April 2021.
  21. ↑ Barker MJ, Greenwood KM, Jackson M, Crowe SF (April 2004). "Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis". Archives of Clinical Neuropsychology. 19 (3): 437–454. doi: 10.1016/S0887-6177(03)00096-9 . PMID   15033227.
  22. ↑ Horsfall JT, Sprague JE (February 2017). "The Pharmacology and Toxicology of the 'Holy Trinity'". Basic & Clinical Pharmacology & Toxicology. 120 (2): 115–119. doi: 10.1111/bcpt.12655 . PMID   27550152. S2CID   25909460.
  23. ↑ "DEA Drugs & Chemicals of Concern "Carisoprodol"". Archived from the original on 17 April 2011. Retrieved 29 April 2011.
  24. ↑ "Schedules of Controlled Substances: Placement of Carisoprodol Into Schedule IV; Announcement of Hearing". Archived from the original on 15 July 2011. Retrieved 19 April 2010.
  25. ↑ "Carisoprodol" (PDF). Drug Enforcement Administration, Diversion Control Division, Drug & Chemical Evaluation Section. U.S. Department of Justice. December 2019.
  26. ↑ Madea B, Musshoff F (May 2009). "Knock-out drugs: their prevalence, modes of action, and means of detection". Deutsches Ärzteblatt International. 106 (20): 341–347. doi:10.3238/arztebl.2009.0341. PMC   2689633 . PMID   19547737.
  27. ↑ "Carisoprodol - an overview | ScienceDirect Topics". www.sciencedirect.com. Retrieved 22 October 2023.
  28. ↑ "What Does a Soma Overdose Look Like?". Project Know. Retrieved 22 October 2023.
  29. ↑ Duke A (22 July 2014). "'Patriot' actress Skye McCole Bartusiak dead at 21". CNN Entertainment. Retrieved 24 February 2019.
  30. ↑ Conermann T, Christian D (2022). "Carisoprodol". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID   31971718 . Retrieved 23 February 2022.
  31. ↑ Dean L (4 April 2017). Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, Dean L (eds.). "Carisoprodol Therapy and CYP2C19 Genotype". Medical Genetics Summaries. PMID   28520382.
  32. ↑ Miller JG, ed. The pharmacology and clinical usefulness of carisoprodol. Detroit:Wayne State University; 1959.
  33. ↑ Berger FM, Kletzkin M, Ludwig BJ, Margolin S (March 1960). "The history, chemistry, and pharmacology of carisoprodol". Annals of the New York Academy of Sciences. 86 (1): 90–107. Bibcode:1960NYASA..86...90B. doi:10.1111/j.1749-6632.1960.tb42792.x. PMID   13799302. S2CID   11909344.
  34. ↑ Bramness JG, Furu K, Engeland A, Skurtveit S (August 2007). "Carisoprodol use and abuse in Norway: a pharmacoepidemiological study". British Journal of Clinical Pharmacology. 64 (2): 210–218. doi:10.1111/j.1365-2125.2007.02847.x. PMC   2000626 . PMID   17298482.
  35. ↑ "Somadril trekkes fra markedet" [Somadril is withdrawn from the market]. Norwegian Medicines Agency (in Norwegian). 20 April 2008. Archived from the original on 16 July 2011. Retrieved 12 March 2010.
  36. ↑ "Carisprodol press release" (PDF). EMEA. Archived from the original (PDF) on 18 July 2009. Retrieved 12 May 2008.
  37. ↑ "Marknadsföringen av Somadril och Somadril comp rekommenderas upphöra tillfälligt" [Marketing of Somadril and Somadril is recommended to cease temporarily] (in Swedish). 16 November 2007. Archived from the original on 23 July 2014. Retrieved 9 May 2009.
  38. ↑ US Department of Justice (2011). "Schedules of Controlled Substances: Placement of Carisoprodol into Schedule IV" (PDF). Federal Register. 76 (238): 77330–77360. Retrieved 1 February 2012.
  39. ↑ "High Cost, No Benefit – The Rheumatologist". the-rheumatologist.org. Archived from the original on 7 May 2015. Retrieved 31 August 2017.
  40. ↑ "NAPRA – Search National Drug Schedule". National Association of Pharmacy Regulatory Authorities. 2009. Archived from the original (ASP) on 1 February 2014. Retrieved 7 January 2014.
  41. ↑ For British Columbia, see library.bcpharmacists.org/D-Legislation_Standards Archived 17 December 2013 at the Wayback Machine
  42. ↑ "One Schoolchild Dies, More Than 50 Suffer Seizures After Consuming Pills in Southeast Sulawesi". Jakarta Globe. 14 September 2017.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.